Evaxion A/S (Form 6-K Filing - Nov 2025)
- Material Event: Company announced expansion of its R&D pipeline.
- Strategic Initiative: Introduction of a new AI-designed precision cancer vaccine candidate.
- Business Focus: Evaxion specializes in AI-Immunology™ powered vaccines.
- Management: The report is signed by Birgitte Rønø, the Interim Chief Executive Officer.
The core focus is the addition of a new clinical development asset leveraging their proprietary AI platform.
Evaxion (EVAX) Pipeline Expansion: New AI Vaccine Candidate
- Announces EVX-04, an